ACHV Share Price | Achieve Life Sciences, Inc. Stock Analysis & Recommendation

Q: How big is Achieve Life Sciences, Inc.?

Market Cap: As of Jun 18, Achieve Life Sciences, Inc. has a market capitalization of 103.36 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Achieve Life Sciences reported net sales of 0.00 million and a net profit of -46.16 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 20.90 million and total assets of 38.63 million.

Q: What does Achieve Life Sciences, Inc. do?

Overview: Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot: Net Profit: -13 Million (Quarterly Results - Mar 2025) Market cap: USD 103.36 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.30 Return on Equity: -439.90% Price to Book: 10.06Contact Details: Address: 520 Pike St Ste 2250, SEATTLE WA : 98101-4013 Tel: ['1 425 6861500', '1 415 3753340'] Fax: 1 302 6365454 Website: http://achievelifesciences.com/

Q: Is Achieve Life Sciences, Inc. overvalued or undervalued?

As of 31 July 2017, the valuation grade for Achieve Life Sciences, Inc. moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, given its negative financial metrics, including a P/E ratio that is not applicable due to losses, a Price to Book Value of 12.92, and an EV to EBITDA of -2.61. In comparison to its peers, Achieve Life Sciences shows a less favorable position; for instance, Abeona Therapeutics, Inc. has an EV to EBITDA of -3.6927, while MediWound Ltd. has a more severe EV to EBITDA of -9.0843. The company's return metrics also reflect its struggles, with a 1-year stock return of -22.74% compared to a 10.26% return for the S&P 500, highlighting its underperformance in the market. Overall, the combination of poor ratios and negative returns suggests that Achieve Life Sciences, Inc. is overvalued in its current state.

Q: Is Achieve Life Sciences, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Achieve Life Sciences, Inc. has changed from bearish to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly MACD is also mildly bullish, suggesting some positive momentum. However, the daily moving averages indicate a mildly bearish stance, and the Bollinger Bands show a mixed signal with weekly mildly bullish and monthly bearish readings. The RSI does not provide any clear signal on either time frame. In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -18.47% versus the S&P 500's 12.22%, and a one-year return of -34.77% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish with mixed indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

304.43 k

Shareholding (Sep 2025)

FII

7.55%

Held by 21 FIIs

DII

74.5%

Held by 18 DIIs

Promoter

3.04%

How big is Achieve Life Sciences, Inc.?

22-Jun-2025

As of Jun 18, Achieve Life Sciences, Inc. has a market capitalization of 103.36 million, with net sales of 0.00 million and a net profit of -46.16 million over the last four quarters. The company reported shareholder's funds of 20.90 million and total assets of 38.63 million as of Dec 24.

View full answer

What does Achieve Life Sciences, Inc. do?

22-Jun-2025

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company focused on developing cytisine for smoking cessation. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $103.36 million.

View full answer

Who are in the management team of Achieve Life Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Achieve Life Sciences, Inc. includes Executive Chairman Richard Stewart, CEO John Bencich, Directors Scott Cormack, Donald Joseph, Martin Mattingly, Jay Moyes, and Independent Director H. Stewart Parker, who oversee the company's strategic direction and operations.

View full answer

Is Achieve Life Sciences, Inc. overvalued or undervalued?

25-Jun-2025

As of July 31, 2017, Achieve Life Sciences, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics and a 1-year stock return of -22.74%, significantly underperforming the S&P 500.

View full answer

Is Achieve Life Sciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Achieve Life Sciences, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly year-to-date and over the past year.

View full answer

Compare Achieve Life Sciences, Inc. with Similar Stocks

Atossa Therapeutics, Inc.Pyxis Oncology, Inc.GlycoMimetics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 224 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.14

Return on Equity

-153.51%

Price to Book

6.65

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-14 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-7.83%

6 Months

39.37%

1 Year

43.88%

2 Years

-13.04%

3 Years

-8.05%

4 Years

-45.73%

5 Years

-68.55%

Achieve Life Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-214.33%

EBIT to Interest (avg)

-19.23

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.30

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

58.02%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.65

EV to EBIT

-3.54

EV to EBITDA

-3.56

EV to Capital Employed

-40.64

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-153.51%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 13 Schemes (14.91%)

Foreign Institutions

Held by 21 Foreign Institutions (7.55%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -15.20% vs -76.06% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.60",
          "val2": "-12.40",
          "chgp": "-17.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.40",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.30",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.40",
          "val2": "-12.50",
          "chgp": "-15.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -33.56% vs 29.72% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-38.80",
          "val2": "-27.00",
          "chgp": "-43.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.20",
          "val2": "2.90",
          "chgp": "-24.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "-0.50",
          "chgp": "-80.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-39.80",
          "val2": "-29.80",
          "chgp": "-33.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.60

-12.40

-17.74%

Interest

0.20

0.40

-50.00%

Exceptional Items

-0.10

-0.30

66.67%

Consolidate Net Profit

-14.40

-12.50

-15.20%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -15.20% vs -76.06% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-38.80

-27.00

-43.70%

Interest

2.20

2.90

-24.14%

Exceptional Items

-0.90

-0.50

-80.00%

Consolidate Net Profit

-39.80

-29.80

-33.56%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -33.56% vs 29.72% in Dec 2023

All Annual Results

Company CV

About Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc.

Pharmaceuticals & Biotechnology

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.

Company Coordinates

Company Details

520 Pike St Ste 2250 , SEATTLE WA : 98101-4013

Tel: 1 425 68615001 415 3753340

http://achievelifesciences.com/

Registrar Details